Merck & Co.

Headquartered in Irvine, California, Edwards Lifesciences develops medical innovations for structural heart disease, critical care, and surgical monitoring. Its R&D focuses on advanced cardiovascular technologies, including transcatheter and surgical heart valves, heart valve repair systems, and hemodynamic monitoring solutions. The company also researches investigational devices and new treatments for cardiovascular diseases. Edwards Lifesciences collaborates with academic institutions, including the Edwards Lifesciences Foundation Cardiovascular Innovation and Research Center at the University of California, Irvine.

Global Headquarters

Manufacturing Facility

New Manufacturing Facility

A pioneering project that developed minimally invasive techniques for replacing heart valves without open-heart surgery, leading to the development of the SAPIEN transcatheter heart valve. Shown here is the EVOQUE Valve replacement systemm the first transcatheter vlve to win FDA approval for the tricuspid valve.

Transcatheter Heart Valve Replacement

Edwards Lifesciences Corp (USA) Hero Image

Edwards Lifesciences (United States) research video

Edwards Lifesciences

Bernard J Zovighian

Scott B Ullem

Todd J Brinton

Joseph Nuzzolese

Platinum designation by the Business Group on Health in 2022 and 2023

Best Employer: Excellence in Health and Well-being

Named in Fortune Magazine's list of best companies to work for

Fortune's 100 Best Companies

Fortune's Most Admired Companies

Global development and commercialization collaboration for three DXd ADCs (antibody-drug conjugates)

Daiichi Sankyo Collaboration

Initiative to support early-stage biomedical startups developing AI and machine learning applications for drug discovery and development

Merck Digital Sciences Studio (MDSS)

Initiative to fund and collaborate with entrepreneurs and early-stage companies focused on delivering transformative healthcare technologies in Asia Pacific and Europe

IDEA Studios

Ongoing research and development efforts related to COVID-19 treatments and vaccines

COVID-19 Research and Response

MSD (United States), also known as Merck & Co., is a multinational pharmaceutical company with over 130 years of history. The company invested $12.2 billion in R&D in 2021. Its research network includes hubs in New Jersey, Pennsylvania, Massachusetts, and California. MSD uses AI, machine learning, and data science to accelerate drug discovery and development, focusing on oncology, vaccines, infectious diseases, immunology, and neuroscience. The Merck Digital Sciences Studio and IDEA Studios support early-stage biomedical startups.

Rahway, NJ (World Headquarters)

West Point, PA

Boston, MA

Cambridge, MA

South San Francisco, CA

San Diego, CA

Upper Gwynedd, PA

London, UK

Singapore

Merck Research Laboratories is MSD's central R&D organization, with major sites in New Jersey, Pennsylvania, Massachusetts, and California. It focuses on drug discovery and development across various therapeutic areas, including oncology, vaccines, infectious diseases, immunology, and neuroscience.

Merck Research Laboratories

KEYTRUDA® is MSD's leading anti-PD-1 therapy, approved for the treatment of various types of cancer, including melanoma, lung cancer, and head and neck cancer. It has been a significant contributor to MSD's oncology portfolio and a key focus of the company's research efforts.

KEYTRUDA® (pembrolizumab)

$12.2 billion invested in research and development as of 2021

Internal R&D Investment

Plans to invest $38 million across Asia Pacific and Europe over three years through IDEA Studios

MSD

Overview

Featured Content

Merck Research Laboratories

Research Areas

Publications per Year

Patents per Year

Location on Map

Related Content

Foreign tech firms building R&D hubs in U.S. in this week’s R&D Power Index

Explore More Labs